Drugs targeting the bone microenvironment: New therapeutic tools in Ewing's sarcoma?

Expert Opinion on Emerging Drugs

Volumn 18, Issue 3, 2013, Pages 339-352

  Redini, Francoise ^a,b   Odri, Guillaume A ^a,b   Picarda, Gaëlle ^a,b   Gaspar, Nathalie ^c   Heymann, Marie Françoise ^a,b,d   Corradini, Nadege ^a,b,e   Heymann, Dominique ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HÔTEL DIEU   (France)

^e Hopital Mere Enfant CHU de Nantes   (France)

Author keywords

Bisphosphonates; Bone resorption; Ewing's sarcoma; Receptor activator of NF B ligand; Tumour microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; FUSION PROTEIN EWS FLI1; GROWTH FACTOR; HYBRID PROTEIN; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; MITHRAMYCIN; NANOPARTICLE; PROTEIN KINASE B; RNA; RNA HELICASE; RNA HELICASE A; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; YK 4279; ZOLEDRONIC ACID;

AMPUTATION; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE; BONE METASTASIS; BONE TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; GASTROINTESTINAL SYMPTOM; GENOMICS; GROWTH INHIBITION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFERTILITY; LEUKOPENIA; LIMB SALVAGE; LIVER TOXICITY; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SURGICAL INFECTION; THROMBOCYTOPENIA; TRANSCRIPTOMICS; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84883201101     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.823948     Document Type: Review

References (112)

1. Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin 1972;22:95-8
2. Paulussen M, Fr€ohlich B, Jürgens H. Ewing tumour: Incidence, prognosis and treatment options. Paediatr Drugs 2001;3:899-913
3. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007;254:1-10
4. Lau YS, Adamopoulos IE, Sabokbar A, et al. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer 2007;96:1716-22
5. Kovar H, Dworzak M, Strehl S, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990;5:1067-70
6. Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421-9
7. Turc-Carel C, Philip I, Berger MP, et al. Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma. CR Seances Acad Sci III 1983;296:1101-3
8. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5
9. Arvand A, Denny CT. Biology of EWS/ ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-54
10. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 2001;25:1061-6
11. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993;90:5752-6
12. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012;44:461-6
13. Erkizan HV, Uversky VN, Toretsky JA. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 2010;16:4077-83
14. Potratz J, Jürgens H, Craft A, Dirksen U. Ewing sarcoma: Biology-based therapeutic perspectives. Pediatr Hematol Oncol 2012;29:12-27
15. Bacci G, Longhi A, Briccoli A, et al. The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2006;65(3):766-72
16. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168-77
17. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J Natl Cancer Inst 2010;102(16):1272-83
18. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11(2):184-92; Review
19. Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47
20. Maksimenko A, Lambert G, Bertrand JR, et al. Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann NY Acad Sci 2003;1002:72-7
21. Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92
22. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009;15:750-6
23. Grohar PJ, Woldemichael GM, Griffin LB, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 2011;103(12):962-78
24. Baruchel S, Pappo A, Krailo M, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur J Cancer 2012;48:579-85
25. Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2012;30:1193-202
26. Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005;11:672-7
27. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, et al. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res 2006;12:6781-90
28. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35
29. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 2012;30:256-62
30. Ho AL, Schwartz GK. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: Unfulfilled promise or a promising beginning? J Clin Oncol 2011;29:4581-3
31. Scotlandi K, Manara MC, Serra M, et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer 2011;47:1258-66
32. Mora J, Rodriguez E, de Torres C, et al. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatr Blood Cancer 2012;58:532-8
33. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007;25:4806-12
34. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/ refractory solid tumors. J Clin Oncol 2011;29:2933-40
35. Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011;29(Suppl):abstract 10005
36. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008;112:2119-29
37. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's Sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9
38. Hotfilder M, Lanvers C, Jurgens H, et al. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol 2002;50:167-9
39. Chao J, Budd GT, Chu P, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 2010;30:547-52
40. Martins AS, Mackintosh C, Martín DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-40
41. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-61
42. Timeus F, Crescenzio N, Fandi A, et al. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep 2008;19:353-9
43. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium. J Clin Oncol 2011;29:839-44
44. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;51:42-8
45. Dubois SG, Shusterman S, Ingle AM, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A children's oncology group study. Clin Cancer Res 2011;17:5113-22
46. Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59:586-8
47. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34
48. Sonnemann J, Palani CD, Wittig S, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer 2011;47:1432-41
49. Javelaud D, Besancon F. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: A mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 2001;20:4365-72
50. Palani CD, Beck JF, Sonnemann J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 2012;30:25-36
51. Puglisi M, van Doorn L, Blanco-Codesido M, et al. A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. J Clin Oncol 2011;29(Suppl):abstract 2518
52. Picarda G, Lamoureux F, Geffroy L, et al. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res 2010;16:2363-74
53. Wang Y, Mandal D, Wang S, et al. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: Imatinib and TRAIL dual therapy. Cancer 2010;116:3892-902
54. Holt SV, Brookes KE, Dive C, Makin GW. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep 2011;25:1177-81
55. Sotillo-Pineiro E, Sierrasesumaga L, Patinno-Garcia A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr Res 2004;55:231-5
56. Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003;63:8338-44
57. Fujimori J, Matsuo T, Shimose S, et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res 2011;29:1707-11
58. Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005;92:1881-91
59. Lanvers-Kaminsky C, Winter B, Koling S, et al. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncol Rep 2005;14:751-8
60. Schuck A, Poremba C, Lanvers C, et al. Radiation-induced changes of telomerase activity in a human Ewing xenograft tumor. Strahlenther Onkol 2002;178:701-8
61. Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009;152:479-96
62. Baliko F, Bright T, Poon R, et al. Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. Am J Pathol 2007;170:1686-94
63. Brail LH, Gray JE, Burris H, et al. A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. J Clin Oncol 2011;29(15s Suppl):abstract 3030
64. Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9:823-7
65. Krishnan K, Khanna C, Helman LJ. The biology of metastases in pediatric sarcomas. Cancer J 2005;11:306-13
66. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-24
67. Sanceau J, Poupon MF, Delattre O, et al. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002;21:7700-9
68. Sanceau J, Wietzerbin J. Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide. Ann N Y Acad Sci 2004;1030:170-8
69. Berghuis D, Santos SJ, Baelde HJ, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011;223:347-57
70. Fujiwara T, Fukushi J, Yamamoto S, et al. Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma. Am J Pathol 2011;179:1157-70
71. Gendy AS, Lipskar A, Glick RD, et al. Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. J Pediatr Surg 2011;46:108-14
72. Lipinski M, Braham K, Philip I, et al. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res 1987;47:183-7
73. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34
74. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76
75. Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/ RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457-75
76. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-78
77. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 2003;14(9):767-71
78. Kubo T, Shimose S, Matsuo T, et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 2006;24(6):1138-44
79. Heymann D, Ory B, Gouin F, et al. Bisphosphonates: New therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004;10:337-43
80. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005;104:1713-20
81. Odri GA, Dumoucel S, Picarda G, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010;70:7610-19
82. Battaglia S, Dumoucel S, Chesneau J, et al. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res 2011;26:2439-51
83. Avnet S, Longhi A, Salerno M, et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 2008;33:1231-8
84. Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 2010;56:738-43
85. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40
86. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6
87. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57
88. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8
89. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-36
90. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-18
91. Lamoureux F, Picarda G, Rousseau J, et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 2008;7:3389-98
92. Rousseau J, Escriou V, Lamoureux F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res 2011;26:2452-62
93. Taylor R, Knowles HJ, Athanasou NA. Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol 2011;225:195-202
94. Picarda G, Matous E, Amiaud J, et al. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. J Bone Oncol 2013; In press
95. Guan H, Zhou Z, Cao Y, et al. VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. Oncol Res 2009;18:117-25
96. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008;2:197-203
97. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
98. Thomas D, Chawla SP, Skubitz K, et al. Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. J Clin Oncol 2008;26(Suppl):abstract 10500
99. Stewart KS, Kleinerman ES. Tumor vessel development and expansion in Ewing's Sarcoma: A review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011;2011:165837
100. Ikeda AK, Judelson DR, Federman N, et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther 2010;9:653-60
101. Nagano A, Ohno T, Shimizu K, et al. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. Int J Cancer 2010;126:2790-8
102. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007;26:2027-38
103. Aryee DN, Niedan S, Kauer M, et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 2010;70:4015-23
104. Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: Regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer 2010;10:372
105. Morton CL, Maris JM, Keir ST, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;58:566-71
106. Pencreach E, Guerin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/ hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009;15:1297-307
107. Hirschberg R. Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care 2012;6:342-7
108. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008;9:1166-72
109. Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: A comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer 2012;20(7):1353-60
110. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7:1823-9
111. Sun L, Yu S. Efficacy and Safety of Denosumab Versus Zoledronic Acid in Patients With Bone Metastases: A Systematic Review and Meta-analysis. Am J Clin Oncol 2012. [Epub ahead of print]
112. Available from: Http://patentscope.wipo. int/search/en/WO2009083614